United Therapeutics Corp (UTHR) Stock Analysis
Verdict: BUY
Elite PAH-franchise cash flows and 86% margins fund a high-risk 'moonshot' pipeline in xenotransplantation—execution vs. insider selling.
Investment score: 68/100
Analysis as of
Is United Therapeutics Corp stock worth reviewing? The TradeMates thesis
Wait for better entry or stabilization following heavy insider selling; fundamentals remain top-tier.
7-factor investment score
- Valuation: 75/100 (weight 20%)
- Financial Health: 90/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 40/100 (weight 15%)
- Insider Sentiment: 20/100 (weight 10%)
- Analyst Consensus: 80/100 (weight 10%)
- Risk-Adjusted Return: 85/100 (weight 15%)
United Therapeutics Corp opportunities and risks
What speaks for UTHR
- Tyvaso expansion into IPF (Idiopathic Pulmonary Fibrosis)
What speaks against UTHR
- Intense Insider Divestment
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| UTHR | 19.1x | 7.6x | 13.4x | 86.6% | 40.6% | 4.2% |
| ALNY | 69.2x | 9.4x | 64.7x | 80.9% | 13.5% | 1.6% |
| RVMD | n/a | 0.0x | n/a | 0.0% | 0.0% | -3.3% |
| NTRA | n/a | 11.7x | n/a | 65.2% | -9.0% | 0.3% |
| BIIB | 20.3x | 2.8x | 11.2x | 69.8% | 13.9% | 9.4% |
| Peer median | n/a | 6.1x | n/a | 67.5% | 6.7% | 1.0% |
Frequently asked questions about United Therapeutics Corp (UTHR)
Is UTHR stock a good investment?
The TradeMates model rates United Therapeutics Corp as BUY with an investment score of 68/100. Wait for better entry or stabilization following heavy insider selling; fundamentals remain top-tier. This is algorithmic model output, not personal investment advice.
Is UTHR stock a buy?
The TradeMates model verdict for UTHR is BUY with an investment score of 68/100. Treat this as a model signal to review, not a personal buy recommendation.